AR038881A1 - Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos - Google Patents
Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellosInfo
- Publication number
- AR038881A1 AR038881A1 ARP030100737A ARP030100737A AR038881A1 AR 038881 A1 AR038881 A1 AR 038881A1 AR P030100737 A ARP030100737 A AR P030100737A AR P030100737 A ARP030100737 A AR P030100737A AR 038881 A1 AR038881 A1 AR 038881A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- alkyl
- alkynyl
- alkenyl
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 5
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000000304 alkynyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 101100440695 Dictyostelium discoideum corB gene Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Compuestos que alteran la actividad de PPAR. También se describen las sales farmacéuticamente aceptables de los compuestos, composiciones farmacéuticamente aceptables que comprenden los compuestos o sus sales, y procedimientos para usarlos como agentes terapéuticos para el tratamiento o prevención de la hiperlipidemia e hipercolesterolemia en un mamífero. La presente también describe procedimientos para la preparación de los compuestos citados. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en la que: W es O, S, CR5R6, -(CH2)p-cicloalquileno, o -(CH2)p-heterocicloalquileno; X0 y X1 son independientemente O o S; Ar1 es un arilo o heteroarilo no sustituido o sustituido; R1, R2, R3 y R4 son independientemente, alquilo, alcoxi inferior, haloalquilo. -O-(CH2)pCF3, halógeno, nitro, ciano, -OH, -SH, -CF3, -S(O)palquilo, -S(O)parilo, -(CH2)mOR7, -(CH2)mNR8R9, -COR7, -CO2H, -CO2R7, o NR8R9, R5 y R6 son independientemente H, alquilo, alquenilo, alquinilo o arilo, o se unen conjuntamente para formar un cicloalquilo o cicloalquenilo de 3 a 7 miembros. R7 es independientemente H, alquilo, alquenilo, alquinilo o arilo; R8 y R9 son cada uno independientemente hidrógeno, alquilo, alquenilo, alquinilo, -COalquilo, -COarilo, cicloalquilo, -CO2alquilo, -CO2arilo, -SO2alquilo, -SO2arilo, o se unen conjuntamente para formar un anillo de 4 a 7 miembros que tiene de 1 a 3 heteroátomos; R10 y R11 son independientemente H, halo, arilo o heteroarilo; m es de 0 a 5; n es de 0 a 5; y p es de 0 a 2; con las siguientes condiciones; que cuando W es O, n = 1, R1 es H, R2 y R4 no son H o R2 y R3 no son H; que cuando W es O, n = 1 y R2 es H, R1 y R3 no son H o R1 y R4 no son H, que cuando W es O, n = 1 y R3 es H, R1 y R4 no son H o R2 y R4 no son H; y que cuando W es O, n = 1 y R4 es H, R1 y R3 no son H o R2 y R3 no son H. Reivindicación 15: Un procedimiento para la preparación de un compuesto que tiene la fórmula (2), el procedimiento caracterizado porque comprende hacer reaccionar el compuesto de estructuras (3) con el de estructura (4) en la que W es O, S, CR5R6, -(CH2)p-cicloalquileno, o -(CH2)p-heterocicloalquileno, X0 y X1 son independientemente O o S; Ar1 es un arilo o heteroarilo no sustituido o sustituido; R1, R2, R3 y R4 son independientemente alquilo, alcoxi inferior, haloalquilo, -O-(CH2)pCF3, halógeno, nitro, ciano, -OH, -SH, -CF3, -S(O)palquilo, -S(O)parilo, -(CH2)mOR7, -(CH2)mNR8R9, -COR7, -CO2H, -CO2R7, o NR8R9, R5 y R6 son independientemente H, alquilo, alquenilo, alquinilo, o arilo, o se unen conjuntamente para formar un cicloalquilo o cicloalquenilo de 3 a 7 miembros. R7 es independientemente H, alquilo, alquenilo, alquinilo o arilo; R8 y R9 son cada uno independientemente H, alquilo, alquenilo, alquinilo, -COalquilo, -COarilo, cicloalquilo, -CO2alquilo, -CO2arilo, -SO2alquilo, -SO2arilo, o se unen conjuntamente para formar un anillo de 4 a 7 miembros que tiene de 1 a 3 heteroátomos; R12 es un alquilo inferior; X es halógeno, m es de 0 a 5; n es de 0 a 5; y p es de 0 a 2; con las siguientes condiciones: que cuando W es O, n = 1, Y está ausente y R1 es H, R2 y R4 no son H o R2 y R3 no son H; que cuando W es O, n =1, Y está ausente y R2 es H, R1 y R3 no son H o R1 y R4 no son H; que cuando W es O, n =1, Y está ausente y R3 es H, R1 y R4 no son H o R2 y R4 no son H; y que cuando W es O, n = 1, Y está ausente y R4 es H, R1 y R3 no son H o R2 y R3 no son H.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36240202P | 2002-03-07 | 2002-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038881A1 true AR038881A1 (es) | 2005-02-02 |
Family
ID=27789157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100737A AR038881A1 (es) | 2002-03-07 | 2003-03-05 | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20030207924A1 (es) |
| EP (1) | EP1482935B1 (es) |
| JP (1) | JP2005528348A (es) |
| KR (1) | KR20040091693A (es) |
| AP (1) | AP2004003124A0 (es) |
| AR (1) | AR038881A1 (es) |
| AT (1) | ATE405260T1 (es) |
| AU (1) | AU2003206059A1 (es) |
| BR (1) | BR0308277A (es) |
| CA (1) | CA2478520A1 (es) |
| CO (1) | CO5601012A2 (es) |
| DE (1) | DE60323060D1 (es) |
| EA (1) | EA200400943A1 (es) |
| EC (1) | ECSP045285A (es) |
| ES (1) | ES2310650T3 (es) |
| HN (1) | HN2003000090A (es) |
| IS (1) | IS7377A (es) |
| MA (1) | MA27181A1 (es) |
| MX (1) | MXPA04007564A (es) |
| NO (1) | NO20044242L (es) |
| OA (1) | OA12780A (es) |
| PA (1) | PA8567801A1 (es) |
| PE (1) | PE20030989A1 (es) |
| PL (1) | PL372969A1 (es) |
| TN (1) | TNSN04168A1 (es) |
| TW (1) | TW200305403A (es) |
| UY (1) | UY27695A1 (es) |
| WO (1) | WO2003074050A1 (es) |
| ZA (1) | ZA200406068B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| PL1638551T3 (pl) * | 2003-05-19 | 2012-05-31 | Irm Llc | Związki i kompozycje immunosupresyjne |
| US7816367B2 (en) * | 2004-02-27 | 2010-10-19 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| EP1745003B1 (en) | 2004-05-05 | 2010-10-27 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| ATE515494T1 (de) | 2004-05-05 | 2011-07-15 | High Point Pharmaceuticals Llc | Neue verbindungen, deren herstellung und verwendung |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| AU2012200214B2 (en) * | 2004-05-14 | 2013-10-24 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| AU2005247473A1 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Substituted triazoles as modulators of PPAR and methods of their preparation |
| EP1749000A4 (en) * | 2004-05-25 | 2009-12-30 | Metabolex Inc | BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF |
| KR100797798B1 (ko) * | 2005-02-25 | 2008-01-24 | 재단법인서울대학교산학협력재단 | 퍼록시솜 증식자 활성화 수용체 델타 리간드 티아졸 유도체및 그의 제조방법 |
| JP4869338B2 (ja) * | 2005-05-07 | 2012-02-08 | ソウル ナショナル ユニバーシティー インダストリー ファンデーション | ペルオキシソーム増殖因子活性化受容体δリガンドの製造方法及びこれを製造するための中間体 |
| US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| RU2412935C2 (ru) | 2005-06-30 | 2011-02-27 | Хай Пойнт Фармасьютикалс, ЛЛС | Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar |
| US8153694B2 (en) * | 2005-07-29 | 2012-04-10 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
| ES2386734T3 (es) | 2005-12-22 | 2012-08-28 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de PPAR-DELTA |
| JP2009132620A (ja) * | 2006-03-07 | 2009-06-18 | Astellas Pharma Inc | フェニルチアゾール誘導体 |
| CA2645719A1 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| AU2007293028B2 (en) | 2006-09-07 | 2012-05-31 | Amgen Inc. | Heterocyclic GPR40 modulators |
| CA2662242C (en) | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| CA2683751C (en) | 2007-04-16 | 2013-01-08 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
| US8030354B2 (en) | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
| WO2009078981A2 (en) * | 2007-12-13 | 2009-06-25 | Sri International | Ppar-delta ligands and methods of their use |
| RU2527177C2 (ru) | 2007-12-20 | 2014-08-27 | Энвиво Фармасьютикалз, Инк. | Четырехзамещенные бензолы |
| MX2010009654A (es) | 2008-03-06 | 2010-09-28 | Amgen Inc | Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos. |
| CA2739888C (en) | 2008-10-15 | 2013-11-19 | Amgen Inc. | Spirocyclic gpr40 modulators |
| EP2540711A4 (en) * | 2010-02-25 | 2014-01-22 | Snu R&Db Foundation | Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds |
| EP3756661A1 (en) | 2013-09-09 | 2020-12-30 | vTv Therapeutics LLC | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
| CZ53699A3 (cs) * | 1996-08-19 | 1999-07-14 | Japan Tobacco Inc. | Deriváty propionové kyseliny a jejich použití |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| US7091225B2 (en) * | 2000-12-20 | 2006-08-15 | Smithkline Beecham Corporation | Substituted oxazoles and thiazoles as hPPAR alpha agonists |
| GB0031107D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0111523D0 (en) * | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
| IL159002A0 (en) * | 2001-06-07 | 2004-05-12 | Lilly Co Eli | Modulators of peroxisome proliferator activated receptors (ppar) |
-
2002
- 2002-12-20 US US10/324,148 patent/US20030207924A1/en not_active Abandoned
-
2003
- 2003-02-24 AP APAP/P/2004/003124A patent/AP2004003124A0/en unknown
- 2003-02-24 MX MXPA04007564A patent/MXPA04007564A/es active IP Right Grant
- 2003-02-24 KR KR10-2004-7013951A patent/KR20040091693A/ko not_active Ceased
- 2003-02-24 CA CA002478520A patent/CA2478520A1/en not_active Abandoned
- 2003-02-24 JP JP2003572567A patent/JP2005528348A/ja not_active Abandoned
- 2003-02-24 EA EA200400943A patent/EA200400943A1/ru unknown
- 2003-02-24 PL PL03372969A patent/PL372969A1/xx not_active Application Discontinuation
- 2003-02-24 BR BR0308277-6A patent/BR0308277A/pt not_active IP Right Cessation
- 2003-02-24 AU AU2003206059A patent/AU2003206059A1/en not_active Abandoned
- 2003-02-24 WO PCT/IB2003/000708 patent/WO2003074050A1/en not_active Ceased
- 2003-02-24 OA OA1200400232A patent/OA12780A/en unknown
- 2003-02-24 DE DE60323060T patent/DE60323060D1/de not_active Expired - Fee Related
- 2003-02-24 AT AT03702943T patent/ATE405260T1/de not_active IP Right Cessation
- 2003-02-24 EP EP03702943A patent/EP1482935B1/en not_active Expired - Lifetime
- 2003-02-24 ES ES03702943T patent/ES2310650T3/es not_active Expired - Lifetime
- 2003-02-27 PA PA20038567801A patent/PA8567801A1/es unknown
- 2003-03-04 PE PE2003000210A patent/PE20030989A1/es not_active Application Discontinuation
- 2003-03-05 AR ARP030100737A patent/AR038881A1/es unknown
- 2003-03-06 HN HN2003000090A patent/HN2003000090A/es unknown
- 2003-03-06 TW TW092104790A patent/TW200305403A/zh unknown
- 2003-03-06 UY UY27695A patent/UY27695A1/es not_active Application Discontinuation
-
2004
- 2004-07-29 ZA ZA200406068A patent/ZA200406068B/en unknown
- 2004-07-29 IS IS7377A patent/IS7377A/is unknown
- 2004-08-24 CO CO04082302A patent/CO5601012A2/es not_active Application Discontinuation
- 2004-08-30 MA MA27839A patent/MA27181A1/fr unknown
- 2004-09-03 TN TNP2004000168A patent/TNSN04168A1/fr unknown
- 2004-09-07 EC EC2004005285A patent/ECSP045285A/es unknown
- 2004-10-06 NO NO20044242A patent/NO20044242L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN04168A1 (fr) | 2007-03-12 |
| IS7377A (is) | 2004-07-29 |
| DE60323060D1 (de) | 2008-10-02 |
| NO20044242L (no) | 2004-10-06 |
| MA27181A1 (fr) | 2005-01-03 |
| OA12780A (en) | 2006-07-07 |
| EP1482935B1 (en) | 2008-08-20 |
| JP2005528348A (ja) | 2005-09-22 |
| EA200400943A1 (ru) | 2005-02-24 |
| WO2003074050A1 (en) | 2003-09-12 |
| ATE405260T1 (de) | 2008-09-15 |
| TW200305403A (en) | 2003-11-01 |
| AP2004003124A0 (en) | 2004-09-30 |
| US20030207924A1 (en) | 2003-11-06 |
| ECSP045285A (es) | 2004-10-26 |
| ES2310650T3 (es) | 2009-01-16 |
| CO5601012A2 (es) | 2006-01-31 |
| HN2003000090A (es) | 2004-05-05 |
| MXPA04007564A (es) | 2004-11-10 |
| KR20040091693A (ko) | 2004-10-28 |
| UY27695A1 (es) | 2003-10-31 |
| BR0308277A (pt) | 2004-12-28 |
| EP1482935A1 (en) | 2004-12-08 |
| PA8567801A1 (es) | 2003-11-12 |
| PL372969A1 (en) | 2005-08-08 |
| AU2003206059A1 (en) | 2003-09-16 |
| ZA200406068B (en) | 2005-09-06 |
| CA2478520A1 (en) | 2003-09-12 |
| PE20030989A1 (es) | 2003-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
| AR038883A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos | |
| AR038882A1 (es) | Compuestos que modulan la actividad de ppar y composicion farmaceutica que los contiene | |
| AR039673A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion | |
| CY1105035T1 (el) | Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες | |
| AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR030959A1 (es) | Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| AR045738A1 (es) | Derivados de bencimidazol n3 alquilados como inhibidores de mek | |
| AR032175A1 (es) | Proceso para la fabricacion de acidos n-aril-antranilicos y sus derivados | |
| AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
| AR035548A1 (es) | Compuestos organicos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| EA202090658A1 (ru) | Ингибиторы кэп-зависимой эндонуклеазы | |
| AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| AR033525A1 (es) | Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
| AR061918A1 (es) | Compuesto biciclico que contiene nitrogeno, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende | |
| CO5261616A1 (es) | Inhibidores no peptidicos de la union celular dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |